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Abstract 
Background: Atrial fibrillation (AF) is one of the most common heart arrhythmias world-wide with 
Americans >40 years old having a lifetime risk of 26% for men and 23% for women. It is estimated that 2.3 
million adults in the United States are currently diagnosed with AF with an expected increase to 5.6 
million by the year 2050. AF is strongly associated with significant cardiovascular (CV) and 
cerebrovascular compilations such as heart failure, stroke and myocardial infarction, as well as non-CV 
causes of death including cancer. Previous investigative focus has been on incidence of AF post-cancer 
diagnosis or as sequela following cancer treatment. This systematic review is aimed at assessing the 
incidence of AF prior to cancer diagnosis and potential utilization in preventative cancer screening. 
Methods: An exhaustive search of current literature was performed using MEDLINE-Ovid, CINAHL and 
Web of Science. Keywords used included: atrial fibrillation, neoplasms and risk. Bibliographies of resulting 
articles were referenced for additional relevant studies. Articles selected for review were published in the 
English language, were exclusive to human subjects and investigated AF preceding cancer diagnosis. 
Articles were assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE). 
Results: The literature search yielded a total of 202 studies; two observational cohort studies met the 
designated criteria for this systematic review. Both observational studies demonstrated a correlation 
between new onset AF and subsequent cancer diagnosis. 
Conclusion: Two observational studies revealed a correlation between new onset AF and cancer 
diagnosis, specifically colorectal and lung cancers. The quality of evidence is moderate given the high 
likelihood of detection bias; additionally these studies could not be directly compared due to the different 
populations included in the research. There is also the question of what to do with this information as 
cancer screening often involves expensive and invasive procedures. Given that AF is one of the most 
common arrhythmias worldwide, it would be unreasonable to subject such a vast number of individuals to 
these unnecessary screenings. However, it is reasonable to expect future studies to investigate this 
correlation in a large diverse population in effort to assess a more accurate level of cancer risk in those 
who are newly diagnosed with AF. 
Keywords: Atrial fibrillation, cancer, neoplasms, and risk 
Degree Type 
Capstone Project 
Degree Name 
Master of Science in Physician Assistant Studies 
Keywords 
Atrial Fibrillation, Neoplasm, Cancer Risk 
This capstone project is available at CommonKnowledge: https://commons.pacificu.edu/pa/607 
Copyright and terms of use 
If you have downloaded this document directly from the web or from CommonKnowledge, see 
the “Rights” section on the previous page for the terms of use. 
If you have received this document through an interlibrary loan/document delivery service, the 
following terms of use apply: 
Copyright in this work is held by the author(s). You may download or print any portion of this 
document for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). 
Except for personal or fair use, you or your borrowing library may not reproduce, remix, 
republish, post, transmit, or distribute this document, or any portion thereof, without the 
permission of the copyright owner. [Note: If this document is licensed under a Creative 
Commons license (see “Rights” on the previous page) which allows broader usage rights, your 
use is governed by the terms of that license.] 
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge 
Rights, Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. 
Email inquiries may be directed to:.copyright@pacificu.edu 
 - 1 - Revised 24 Apr 2017 
The Correlation with New-Onset Atrial Fibrillation and 
Increased Cancer Risk 
 
 
 
 
 
 
Jessica B. Sclafani PA-S 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR 
For the Masters of Science Degree, August 2017 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
 
 
 
 
 
 
 - 2 - Revised 24 Apr 2017 
BIOGRAPHY 
 
Jessica Sclafani is originally from Connecticut where she received her undergraduate 
degree in kinesiology from Sacred Heart University. Following completion of her 
undergraduate degree, she began working as a health and wellness consultant for GE 
corporate. Subsequently, her strong interest in cardiology led her to work as a certified 
clinical research coordinator for Cardiology Associates of Fairfield County in 
Connecticut. She is currently attending the physician assistant program at Pacific 
University with the ambition to pursue a career in pediatric cardiology following 
graduation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 3 - Revised 24 Apr 2017 
ABSTRACT   
 
Background: Atrial fibrillation (AF) is one of the most common heart arrhythmias 
world-wide with Americans >40 years old having a lifetime risk of 26% for men and 
23% for women. It is estimated that 2.3 million adults in the United States are currently 
diagnosed with AF with an expected increase to 5.6 million by the year 2050. AF is 
strongly associated with significant cardiovascular (CV) and cerebrovascular 
compilations such as heart failure, stroke and myocardial infarction, as well as non-CV 
causes of death including cancer. Previous investigative focus has been on incidence of 
AF post-cancer diagnosis or as sequela following cancer treatment. This systematic 
review is aimed at assessing the incidence of AF prior to cancer diagnosis and potential 
utilization in preventative cancer screening.  
 
Methods:  An exhaustive search of current literature was performed using MEDLINE-
Ovid, CINAHL and Web of Science. Keywords used included: atrial fibrillation, 
neoplasms and risk. Bibliographies of resulting articles were referenced for additional 
relevant studies.  Articles selected for review were published in the English language, 
were exclusive to human subjects and investigated AF preceding cancer diagnosis. 
Articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE). 
 
Results:  The literature search yielded a total of 202 studies; two observational cohort 
studies met the designated criteria for this systematic review. Both observational studies 
demonstrated a correlation between new onset AF and subsequent cancer diagnosis.  
 
Conclusion:  Two observational studies revealed a correlation between new onset AF 
and cancer diagnosis, specifically colorectal and lung cancers. The quality of evidence is 
moderate given the high likelihood of detection bias; additionally these studies could not 
be directly compared due to the different populations included in the research. There is 
also the question of what to do with this information as cancer screening often involves 
expensive and invasive procedures. Given that AF is one of the most common 
arrhythmias worldwide, it would be unreasonable to subject such a vast number of 
individuals to these unnecessary screenings. However, it is reasonable to expect future 
studies to investigate this correlation in a large diverse population in effort to assess a 
more accurate level of cancer risk in those who are newly diagnosed with AF.  
 
Keywords:  Atrial fibrillation, cancer, neoplasms, and risk 
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The Correlation with New-Onset Atrial Fibrillation and 
Increased Cancer Risk 
 
BACKGROUND 
Atrial fibrillation (AF) is one of the most common heart arrhythmias world-wide 
with Americans >40 years old having a lifetime risk of 26% for men and 23% for 
women1 confirmed by a European population study2 with lifetime risk of 23.8% for men 
and 22.3% for women. It is estimated that 2.3 million adults in the United States are 
currently diagnosed with AF with an expected increase to 5.6 million by the year 
2050.3,4 Approximately 75% of patients diagnosed with AF will have a life threatening 
hospitalization or expire due to complications within 20 years of their diagnosis, which 
is a 3-fold increase compared to those without an AF diagnosis.5 AF is strongly 
associated with significant cardiovascular (CV) and cerebrovascular complications such 
as, heart failure, stroke and myocardial infarction. AF is also associated with non-CV 
causes of death, most specifically: cancer.3  
While heart disease remains the leading cause of death in the United States, 
cancer follows closely behind as the second most prevalent cause of death.6 The World 
Health Organization reported that in the year 2012, 14.1 million people were newly 
diagnosed with cancer and of those diagnosed, 8.2 million resulted in death.7 The CDC 
estimates that by the year 2025, 19.3 million new cancer cases per year are expected to 
be diagnosed.8 The leading cancer deaths across all genders and races in the United 
States include: lung, breast and colorectal cancer.8  
Current focus has been placed on the early detection and prevention of cancer 
due to worldwide disease prevalence, as well as, the emphasis on preventative medicine 
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in recent years. Previous studies9,10 have investigated the incidence of AF post-cancer 
diagnosis, or as sequela post-cancer treatment. A correlation between cancer diagnosis 
and/or treatment and new AF diagnosis has been established. Specifically looking at 
lung cancer requiring thoracic surgery, rates of post-operative AF diagnosis have been 
reported ranging from 6 to 32%. Similar findings have resulted post-colorectal cancer 
resection.  Although the true mechanism of this connection remains unknown, theories 
focus their etiology on the increased inflammatory state or hypercoagulability in cancer 
patients, as well as, tumor effect and co-morbid states. 9,10 Few studies have researched 
the incidence of AF prior to cancer diagnosis for its potential screening use. This 
systematic review aims to assess the incidence of cancer diagnosis following new onset 
of AF and its potential utilization in preventative cancer screening.  
 
METHODS 
An exhaustive search of current literature was performed using MEDLINE-Ovid, 
CINAHL and Web of Science. Keywords used included: atrial fibrillation, neoplasms 
and risk. Bibliographies of resulting studies were referenced for additional relevant 
studies.  Articles selected for review were published in the English language, were 
exclusive to human subjects and observed AF preceding cancer diagnosis. Articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE).11 
 
RESULTS 
The literature search yielded a total of 202 studies. Duplicate studies were 
excluded and the remaining results were screened for relevance based on eligibility 
 - 9 - Revised 24 Apr 2017 
criteria. Two observational cohort studies12,13 met the designated criteria for this 
systematic review, see Table I. 
Conen et al 
This prospective cohort study12 sought to investigate the increased risk for cancer 
in women newly diagnosed with AF. The study population included 34 691 women age 
45 or greater previously enrolled in a randomized controlled trial of aspirin and vitamin 
E for the prevention of CV disease and cancer. Women were followed from enrollment 
in 1993 to 1995 through the end of the study period on March 31, 2004 with an optional 
additional observational cohort study. Women previously diagnosed with cancer, AF or 
major CV events were excluded from the cohort study. Those lost to follow up or who 
did not consent to the additional observational study were not included in this analysis.  
AF diagnosis was self-reported on questionnaires administered during the study period. 
For those who reported at least one episode of AF, medical records were reviewed and 
AF diagnosis confirmed by either electrocardiogram or medical documentation. Cancer 
was similarly self-reported on study questionnaires by participants with medical record 
review and confirmation via cytology, pathology or, if unavailable, by radiographic or 
laboratory evidence.12  
Primary endpoint for the study was invasive cancer with secondary outcomes of 
incidence of breast, colorectal and lung cancer. Considerations were made for the 
following: age, randomization assignment, education level, race, height, weight, 
hypertension, hypercholesterolemia, diabetes, smoking, alcohol use, physical activity, 
hormone replacement therapy, recent cancer screening and non fatal CV events. 
Demographics, risk factors and study outcomes were assessed via self-reported 
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questionnaire every 6 months during year one of follow up and every 12 months beyond. 
Cancer diagnosis was separated into 0-3 months, 3-12 months and greater than 12 
months from the time of AF diagnosis. Risk of incident AF after new cancer diagnosis 
was also monitored, which is where the majority of previous research is focused. Two 
sensitivity analyses were performed and considered. One in which the adjustment for 
screening procedures was removed and the second where only incidence of AF 
diagnosed after 2006 were considered as this is when the AF validation process was 
initiated. The previous randomization was considered as well as a separate analysis 
performed utilizing only the randomized time period. Original study randomization 
therapies of ASA or vitamin E were not found to have significant effect on the outcome 
of AF or cancer.12 
 During the study period 1467 women were diagnosed with new onset AF and 
5130 with cancer. Those diagnosed with AF were found to be older, taller, had a greater 
BMI, higher prevalence of comorbidities, lower education level and were more likely to 
be Caucasian. Those diagnosed with cancer were found to have similar characteristics 
with the exclusion of education level and a higher incidence of smoking. Of those 
diagnosed with cancer 147 (10%) had a preceding AF diagnosis. The incidence of cancer 
was 0.8 per 100 among those without an AF diagnosis versus 1.4 per 100 person-years 
of follow-up in those with an AF diagnosis. The multi variable adjustment hazard ratio 
(HR) for AF association with cancer was 1.48; 95% CI, 1.25-1.75; P < .001. The 
randomization therapies were not found to have an impact on these results, P = .27 and 
.16 for interaction via subdistribution hazard models. Risk of cancer was found to be 
highest within the first 3 months of AF diagnosis (Adjusted HR, 3.5; 95% CI, 2.05-6.10; 
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P < .001), the risk remained increased beyond 1-year post diagnosis (Adjusted HR 1.42; 
95% CI, 1.18-1.71; P < .001). Analysis of cancer types revealed the highest association 
between new onset AF and colon cancer.12 
 The authors acknowledge the possibility of detection bias as women diagnosed 
with new onset AF were more exposed to healthcare and therefore had access to 
screenings and detection of disease. Colon cancer discovery as a result of increased 
colorectal bleeding caused by anticoagulants used to treat AF was additionally 
recognized as possible detection bias. Cancer screening measures were not increased in 
patients diagnosed with AF nor did an adjustment for screening affect the resulting 
statistics. Strengths of this study included the large population size and the length of 
time for which data remained available with minimal missing information. The authors 
accounted for many possible confounders in their statistical analysis with consistent 
outcomes.12 
Oatenfeld et al 
This prospective cohort study13 observed the Danish population from January 1, 
1980 through December 31, 2011. The Danish National Registry of Patients was utilized 
to identify all persons with new diagnosis of AF. The method of identification was based 
on ICD-8 codes until the ICD-9 codes were established in 1993. Researchers further 
collected data on comorbidities of those diagnosed with AF including diabetes, 
hyperthyroidism, COPD, alcoholism and surgeries within 3 months of AF diagnosis. 
These comorbidities were ranked based on the Charlson score as low, medium or high. 
To determine cancer risk, the Danish Cancer Registry was utilized to link any citizen 
diagnosed with new onset AF with a cancer diagnosis if one was present. Data collected 
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included cancer stage at diagnosis and the degree of metastatic versus localized cancers. 
Any person diagnosed with cancer prior to their AF diagnosis was excluded from the 
study.13  
Patients were followed from the time of their AF diagnosis to study endpoint, 
death or emigration. Cancer risk was gauged via Statistical Information on Recidivism 
(SIR) by comparing cancer risk amongst study patients diagnosed with AF versus 
expected risk within the Danish population. Expected risk was based on national 
incidence and quantified as though those in the study had the same risk as the general 
population. During the study period 269 742 patients were diagnosed with new onset 
AF. Of those 6656 patients were diagnosed with cancer resulting in an absolute risk of 
2.5% (95% CI, 2.4%-2.5%). There were no significant differences between genders or age 
groups, except for a lower relative risk amongst the 0-29 year group (0.95%; 95% CI, 
0.63-2.38). At the 3-month follow up visit the SIR was 5.11% (95% CI, 4.99 – 5.24). 
Beyond the 3-month follow up cancer risk remained increased, however, continued to 
decrease over time. The most prevalent cancers were lung, kidney and colon. An 
increased risk of non-Hodgkin lymphoma as well as cancers associated with obesity and 
smoking were also observed.  Information on cancer spread was available for 26 528 of 
the 34 962 patients in the study. Within 3 months of follow up for new onset AF, 
metastatic cancer was diagnosed in 2848 compared to the expected 406 (SIR, 7.02; 95% 
CI, 6.76 – 7.28). Localized cancer was diagnosed in 2129 patients compared to the 
expected 603 (SIR 3.53; 95% CI, 3.38- 3.68). In an analysis limited to the patients with 
AF as the primary diagnosis, 2365 cancers were diagnosed within the first 3 months of 
AF diagnosis compared to the expected 757 cases (SIR 3.13%; 95% CI, 3.00-3.25) with 
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an absolute risk of 1.5% (95%CI, 1.4-1.5). When further excluding patients who received 
both diagnoses at the same visit the 3-month SIR was 1.63% (95%CI, 1.56-1.7) with an 
absolute risk of 0.8% (95% CI, .77%-.84%).13  
 Authors of this study concluded that it was likely that occult cancer was already 
present at the time of AF diagnosis, as previous research has indicated; however, 
researches believe new onset AF may be the first indicator of occult cancer. The 
strengths of this study included the population-based design under the tax-supported 
health system of Denmark. Authors believe limitations of the study may include coding 
errors within the registry or errors leading to overestimation of risk. Despite these 
limitations it was concluded that the relative risks may be underestimated based on 
exclusions made during analysis and removal of data on patients diagnosed with AF and 
cancer at the same visit.13  
  
DISCUSSION 
 While previous studies have demonstrated a significant risk for AF after cancer 
diagnosis or during cancer treatment, few have looked at the risk of cancer diagnosis 
after new onset AF. This systematic review was able to identify two published articles12,13 
that addressed the question of whether or not new onset AF may be an indicator of 
undiagnosed cancer. Both articles acknowledge the possibility of detection bias based on 
heath care access as well as possible overestimation of risk. These studies were 
evaluated via the GRADE11 method, results can be found in Table I. 
These studies conclusively established an increased risk of cancer in those 
individuals newly diagnosed with AF, specifically for colon and lung cancer, 2 of the top 
3 leading causes of cancer deaths in the United States.7,8,12,13 The greatest incidence of 
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cancer diagnosis in both populations studied is recognized to be within 0-3 months 
following new AF diagnosis with a lasting increased risk for up to the first 12 months 
after diagnosis.12,13 Ostenfeld et al13 additionally found an increased risk for non-
Hodgkin lymphoma and kidney cancer versus Conen et al12 found an additional 
increased risk for breast cancer. The increased breast cancer risk is likely due to 
population bias as this study observed only women. There is a strong possible detection 
bias in diagnosis of colon cancer in those with AF who are treated with anticoagulants as 
there is an increased risk of gastrointestinal bleed with such therapies warranting 
medical exploration and likely detection of colon cancer if present; this is acknowledged 
by researchers in both articles.  
AF is diagnosed via a non-invasive and cost effective electrocardiogram tracing 
while a cancer diagnosis may consist of a series of labs and often an invasive biopsy. To 
screen every individual newly diagnosed with AF for cancer would be an enormous cost 
burden and result in unnecessary invasive procedures. It may be reasonable for those 
with an increased risk of colorectal, breast, or lung cancer who develop AF to 
aggressively pursue risk factor reduction with baseline minimally invasive tumor marker 
laboratory tests to monitor for potential cancer development. 
           According to the CDC, colorectal cancer is the second leading cause of cancer 
related death with lung cancer being the first amongst men and women in the United 
States.8 A prospective study14 conducted on a Veteran’s Affairs (VA) population 
investigating diseases that precede colon cancer found a significant increase in AF 
diagnosis prior to colon cancer diagnosis with an odds ratio of 1.34; 95%CI 1.16-1.55. In 
follow up to the VA study, a case control study15 was performed in Italy observing the 
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incidence of AF among 456 patients diagnosed with colon cancer compared to a control 
group of 791 patients without colon cancer. This study found that 5% of the patients 
diagnosed with colon cancer had an established diagnosis of AF versus 2% of the control 
group. This  revealed a more than double the incidence of AF among patients diagnosed 
with colon cancer.15 It is hypothesized that occult cancer is already present at the time of 
AF diagnosis and that AF may be the earliest indicator.13,15  
             In addition, the REASONS prospective cohort study16 analyzed a population of 
individuals living in North Carolina, South Carolina, Georgia, Alabama, Mississippi, 
Tennessee, Arkansas and Louisiana to observe racial and regional cause of stroke. A 
sub-analysis of this information divided the study population into subgroups to 
including age, race, gender, CV risk factor and inflammatory marker measurements. A 
total of 15 428 individuals qualified for this sub-analysis in which participants were then 
placed into AF or no AF groups as well as cancer or no cancer groups. Figure I 
graphically depicts the results which show a higher incidence of cancer in those 
diagnosed with AF across all subgroups.16 
          Cancer and AF have several shared risk factors including age, smoking, obesity and 
metabolic disorders.2,10,16,17,18 There are several theories as to the connection between AF 
and cancer of which the most widely agreed upon is the increased inflammatory state 
associated with both AF and cancer10,17,18; however, in general the mechanism of AF 
remains inadequately understood. Future research is warranted as this systematic 
review demonstrates an established increased risk of cancer in those diagnosed with 
new-onset-AF specifically the leading causes of cancer death: lung, breast and 
colorectal. While theories exist as to the physiologic connection between AF and cancer 
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there is no widely accepted theory. A true understanding of the mechanism connecting 
these disease states would provide a platform for preventative screening and possible 
therapies. A large study observing a diverse population is required to validate these 
findings. The articles addressed in this review had populations limited to the primarily 
Caucasian population of Denmark13 and an all female population.12   
CONCLUSION 
The studies evaluated in this systematic review revealed a significant increased 
incidence in cancer diagnosis amongst those diagnosed with new onset AF. While both 
studies observed the risk increased specifically in colon and lung cancer, the populations 
were not able to be compared directly as Conen et al12 observed only females while 
Ostenfeld et al13 observed an entire primarily Caucasian country’s population. Through 
larger diverse population observational studies, new onset AF has the potential to 
become recognized as an important risk factor in the screening for cancer.  
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Table I: Quality Assessment of Reviewed Studies 
 
Study Design 
Downgrade Criteria Upgrade 
Criteria 
 
Quality Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Conen et 
al12 
Cohort Not Serious Not Serious Not Serious Not Serious Unlikely Residual 
confoundinga 
 
Moderate 
Ostenfeld 
et al13 
Cohort Not Serious Not Serious Not Serious Not Serious Unlikely Residual 
confoundinga 
 
Moderate 
a Both studies considered all reasonable confounders and multivariable adjusted their risk calculations based on any possibility of 
demographic or exposure bias with a significant risk remaining despite these considerations 
 
 
 
 
 
   
Figure I: Prevalence of AF in Sub-Groups of Cancer vs. Non-Cancer Patients 
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